Despite of extensive genetic analysis of acute myeloid leukemia (AML), we still 25 do not understand comprehensively mechanism that promote disease relapse 26 from standard chemotherapy. Based on recent indications for non-genomic 27 inhibition of tumor suppressor protein phosphatase 2A (PP2A) in AML, we 28 examined mRNA expression of PP2A inhibitor proteins in AML patient samples. 29
CIP2A, SET, PME1, ARPP19 and TIPRL, greatly exceeds the frequency of 72 genetic mutations on PP2A genes 9 . However, while in many solid cancers the 73 non-genomic inhibition of PP2A has already been extensively studied, in 74 haematological malignancies this understanding is still relatively poor. 75 76 Due to recent discovery of PP2A inhibition as a putative AML driver mechanism 77 10 , PAIPs are also emerging as potentially interesting AML marker genes. 78
However, none of the published studies have compared systematically the 79 expression profiles of different PAIPs in AML. One of the PAIPs, ARPP19 (cAMP-80 regulated phosphoprotein 19), a member of the alpha-endosulfine (ENSA) family, 81 has been shown to promote G2/M transition and the mitotic state in solid cancer 82 cells 11 . ARPP19 overexpression has been linked to tumor progression in solid 83 cancers such as glioma 12 and hepatocellular carcinoma 13 but its role in AML has 84 not been studied as yet. 85
86
In this first study addressing landscape of PAIPs in AML, we discovered low 87 ARPP19 mRNA expression as a novel predictive marker for estimation of low 88 relapse risk in patients with AML. We also identified ARPP19 as an AML 89 oncoprotein that increases cell viability and enhances expression of oncoproteins 90 MYC and CDK1 and also of another oncogenic PP2A inhibitor protein CIP2A. 91
Most importantly, we found that ARPP19 mRNA expression and its role as a 92 predictive relapse marker was independent of current genetic risk classification 93 schemes suggesting that ARPP19 mediates its functions in AML by mechanisms 94 that are independent of the known genetic mechanisms. Together these novel 95 results identify ARPP19 as a potential AML oncoprotein with clinical relevance. 96
Materials and methods 97 98

Patient cohorts 99
Patient cohort1: Consecutive bone marrow samples were collected between 100 January 2000 and July 2010, a total of 80 patients aged 18-65 diagnosed with de 101 novo or secondary AML at Turku University Hospital (TYKS). Patients with acute 102 promyelocytic leukemia (t(15;17)(q22;q12)) were excluded from this cohort. 103
Patient characteristics are presented in supplemental Table 1 . Median age for 104 the patients was 50 years (Q1=38.8, Q3=58.0), median overall survival was 5.4 105 years (95% CI, 2.8 to 7.9) and median follow-up time was 5.4 years (range 6 days 106 -16 years). The ELN risk classification, based on cytogenetic and molecular 107 findings, was used as risk stratification (supplemental Table 2 ). Most patients (76) 108
were enrolled in the Finnish Leukemia Study Group prospective protocols 109 (supplemental Table 3 ). 32 patients were treated according to AML92 Table 1 ). The representative 268 nature of the study material was also confirmed by significant association 269 between risk groups and overall survival (OS) of patients in this cohort ( Figure  270 1a, p=0.003 by log-rank test). Five-year survival rate was 81% for the patients in To explore functional role of ARPP19 in AML cells, we used four established cell 340 lines that were chosen on the basis of their diverse genetic background (DSMZ 341 Scientific data). Consistent with patient samples at mRNA level (Figure 1f) , 342
Western blot analysis demonstrated variable ARPP19 protein expression levels 343 between AML cell lines (Figure 2a and 2b) . Interestingly, eventhough ARPP19 344 and CIP2A did not strongly correlate at mRNA level (Figure 1i ), ARPP19 protein 345 expression correlated CIP2A protein expression in these cell lines (Figure 2a Table  419 7), showed statistically significant association with the risk groups. On the other 420 hand, and as expected, EVI1 mRNA expression at diagnosis was significantly 421 different between the three risk groups, and its expression increased in relation 422 univariable analysis also revealed that ARPP19 (Table 1 , p=0.007, HR 2.87 (95% 484 CI, 1.33 to 6.22)), EVI1 (p=0.0005, HR 1.26 (95% CI, 1.11 to 1.44)), and SET 485 (p=0.035, HR 2.36 (95% CI, 1.06 to 5.25)) expressions at the diagnosis had 486 SET, TIPRL, PME1, EVI1 and WT1 at diagnosis. In the initial model the significant 492 markers for time to relapse were diagnosis age (p=0.024), NPM1 mutation 493 positivity (p=0.035), EVI1 (p=0.0004), SET (p=0.021) and ARPP19 (p=0.0008) 494 mRNA expression. After excluding the non-significant markers, age (p=0.023, 495 HR: 1.07, 95% CI, 1.01 to 1.13), NPM1 mutation positivity (p=0.048, HR: 0.031 496 (95% CI, 0.001 to 0.97), EVI1 (p=0.0005, HR: 1.41 (95% CI, 1.16 to 1.71), SET 497 (p=0.0097, HR: 0.12 (95% CI, 0.022 to 0.59) and ARPP19 (p=0.0001, HR: 58.8 498 (95% CI, 7.39 to 467.2) expressions were independent prognostic factors for the 499 time to relapse (Table 2) . 500 501 Very importantly, Cox's type1 analysis revealed that ARPP19 expression 502 (p=0.005) gave additional information in AML patients relapse prognosis after risk 503 group, and EVI1 mRNA expression, were depicted as significant factors in 504 explaining the probability of relapse. Receiver operating characteristic (ROC) 505 analysis also showed that ARPP19 together with EVI1 could be more accurate 506 predictor of relapse than EVI1 alone (EVI1 AUC 0.69 (95% CI, 0.48 to 0.89), 507 ARPP19 AUC 0.67 (95% CI, 0.48 to 0.83) and ARPP19+EVI1 AUC together 0.76 508 (95% CI, 0.57 to 0.91); EVI1 AUC vs. EVI1+ARPP19 AUC p=0.07 by Chi-509 Squared test, supplemental Figure 3b ). 510
511
Together these results identify low ARPP19 expression as a novel risk group 512 independent gene associated with low relapse risk in human AML. Importantly, 513 the predictive role of ARPP19 was additive when the currently used 514 clinicopathological markers, including risk group classification, were taken into 515 account. 516 517 Survival analysis based on PP2A inhibitor protein mRNA expression in 518 AML patients 519 520 Next, we analyzed whether the risk group independent predictive role of ARPP19 521 for relapse is reflected in the overall survival of all 80 cases treated with intensive 522 chemotherapy in cohort1. For this purpose, we used Cox's proportional 523 multivariable hazard model for OS, which included diagnosis age, FLT3-ITD 524 status, NPM1 mutation status, and diagnosis phase mRNA expression levels of 525 ARPP19, CIP2A, SET, TIPRL, PME1, EVI1 and WT1. In the initial model the 526 significant markers for OS were diagnosis age (p=0.024) and EVI1 (p=0.0127) 527 mRNA expression. After excluding the non-significant markers, diagnosis age 528 (Table 2 , p=0.0004, HR: 1.07 (95% CI, 1.03 to 1.11), NPM1 mutation positivity 529 (p=0.0165, HR: 0.21 (95% CI, 0.057 to 0.75)) and EVI1 expression (p=0.0263, 530 HR: 1.14 (95% CI, 1.02 to 1.28) were found as independent prognostic factor for 531
OS. Notably, out of the PAIPs, only ARPP19 mRNA expression was found as an 532 independent prognostic factor for OS, and its HR was found to be even higher 533 than either EVI1 or diagnosis age (p=0.0456, HR: 2.05 (95% CI, 1.01 to 4.15)). 534
535
To evaluate these results in an independent AML patient cohort, we used RNA 536 sequencing dataset available from TCGA (TCGA LAML, survival data available 537 for n=160, exon expression IlluminaHiSeq) 23 and analyzed the correlation 538 between OS and ARPP19 gene expression using UCSC Xena Browser 24 . Based 539 on median as a cut-off value, the data was categorized into two groups, low 540 ARPP19 and high ARPP19. Consitent with other results, ARPP19 expression 541 alone was able to act as an independent prognostic marker for OS ( Figure 4e) . 542 Patient group with low ARPP19 gene expression (n = 82) showed better OS 543 (p=0.019 by log-rank test) than the patients with high ARPP19 expression (n = 544 78). PAIPs has been reported to promote malignant growth of several cell types 9,25 , 590
including leukemic cells 10 . In AML, SET promotes both malignant growth and 591 drug resistance 17,26 , and CIP2A inhibition in AML cells reduces proliferation and 592 MYC expression 27 . Prevalent role for PP2A inhibition in AML 10 , and in other 593 cancer types 9,25 , provides a strong scientific rationale for clinical association 594 between low ARPP19 expression and a lower risk for AML relapse newly 595 discovered in this study. In a direct support of oncogenic role of ARPP19 in AML, 596
we demonstrate that ARPP19 knockdown decreased expression of a well-597 validated oncogenic PP2A target MYC. Interestingly, our data also show that 598 ARPP19 positively regulates CIP2A protein expression even though we did not 599 observe any particular strong assocation between ARPP19 and CIP2A mRNA 600 expression in AML patient samples. This data suggests that similarly to CML 19,28 , 601 CIP2A may be regulated at the protein level in AML. In fact, a recent study did 602 indicate that CIP2A protein levels function as a biomarker for AML 29 . Thereby, 603
further studies on regulation of CIP2A protein expression by ARPP19 in AML 604 cells are clearly warranted. The functional hierarchy between ARPP19 and 605 CIP2A proteins provides a plausible explanation why ARPP19 may have a 606 stronger clinical role than CIP2A in AML. This can be rationalized as ARPP19 607
can control both directly its own PP2A/B55-subunit targets 30 , but also PP2A/B56-608 subunit targets via CIP2A 22 (Figure 3c ). Therapeutically, it is tempting to envision 609 that decreased PP2A activity due to ARPP19 overexpression could be restored 610 by blocking ARPP19 effects on PP2A. However, development of ARPP19 611 targeted therapies awaits for structural analysis of the ARPP19 protein. 612
613
In summary, our results identify ARPP19 as a potential novel AML oncoprotein. 614
Most importantly, ARPP19 gene expression, and its relapse predicting role were 615 found to be independent of the current genetic risk classification. This suggests 616 that better understanding of ARPP19 function in AML could provide clinically 617 relevant additional value to existing diagnostic and therapeutic approaches. 618 manuscript, with input from O.K., U.S., E.L., V.K. and M.I-R. All authors reviewed 643 and approved the final manuscript. 644
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